Drug Interaction Report

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of apremilast, which is primarily metabolized by the isoenzyme in vitro. According to the product labeling, administration of a single 30 mg oral dose of apremilast with the potent CYP450 inducer rifampin (600 mg once daily for 15 days) resulted in decreases of apremilast peak plasma concentration (Cmax) and systemic exposure (AUC) by 43% and 72%, respectively.

MANAGEMENT: The possibility of a diminished therapeutic response to apremilast should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic effects of apremilast should be monitored more closely following the initiation or withdrawal of a CYP450 3A4 inducer.

ADJUST DOSING INTERVAL: Food may reduce as well as delay the absorption of dabrafenib. In study subjects, administration of dabrafenib with a high-fat meal decreased peak plasma concentration (Cmax) and systemic exposure (AUC) by 51% and 31%, respectively, and delayed median Tmax by approximately 3.6 hours compared to administration in the fasted state.

MANAGEMENT: Dabrafenib should be taken at least 1 hour before or 2 hours after a meal.